Functional co-expression of CYP2D6 and human NADPH-cytochrome P450 reductase in Escherichia coli

Pharmacogenetics

Volumn 8, Issue 1, 1998, Pages 33-42

  Pritchard, Michael P ^a   Glancey, Michael J ^a   Blake, Jennifer A R ^a   Gilham, David E ^b   Burchell, Brian ^a   Wolf, C Roland ^a   Friedberg, Thomas ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Bufuralol; CYP2D6; Escherichia coli; Heterologous expression; NADPH cytochrome P450; Reductase

Indexed keywords

BUFURALOL; COMPLEMENTARY DNA; CYTOCHROME P450; CYTOCHROME P450 REDUCTASE; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE FERRIHEMOPROTEIN REDUCTASE;

ALLELE; ARTICLE; BACTERIAL MEMBRANE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG METABOLISM; ESCHERICHIA COLI; GENETIC VARIABILITY; HUMAN; IMMUNOBLOTTING; MOLECULAR CLONING; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; SPECTROSCOPY; XENOBIOTIC METABOLISM;

ADRENERGIC BETA-ANTAGONISTS; BASE SEQUENCE; CYTOCHROME P-450 CYP2D6; DNA PRIMERS; ESCHERICHIA COLI; ETHANOLAMINES; GENE EXPRESSION; HUMANS; KINETICS; METOPROLOL; NADPH-FERRIHEMOPROTEIN REDUCTASE; PLASMIDS; POLYMORPHISM, GENETIC; RECOMBINANT PROTEINS;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

EID: 0031882999     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199802000-00005     Document Type: Article

References (33)

1. Aoyama T, Yamano S, Guzelian PS, Gelboin HV, Gonzalez FJ. Five of 12 forms of vaccinia virus-expressed human hepatic cytochrome P450 metabolically activate aflatoxin B1. Proc Natl Acad Sci USA 1990; 87, 4790-4793.
2. Barnes HJ, Arlotto MP, Waterman MR. Expression and enzymatic activity of recombinant cytochrome P450 17α-hydroxylase in Escherichia coli. Proc Natl Acad Sci USA 1991; 88, 5597-5601.
3. Blake JAR, Pritchard M, Ding S, Smith GCM, Burchell B, Wolf CR, Friedberg T. Coexpression of a human P450 (CYP5A4) and P450 reductase generates a highly functional monooxygenase system in Escherichia coli. FEBS Lett 1996; 397, 210-214.
4. Crespi CL, Steimel DT, Penman BW, Korzekwa KR, Fernandez-Salguero P, Buters JTM, Gelboin HV, Gonzalez FJ, Idle JR, Daly AK. Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374. Pharmacogenetics 1995; 5, 234-243.
5. Dong J, Porter TD. Coexpression of mammalian cytochrome P450 and reductase in Escherichia coli.. Arch Biochem Biophys 1996; 327, 254-259.
6. Ellis SW, Ching MS, Watson PF, Henderson CJ, Simula AP, Lennard MS, Tucker GT, Woods HF. Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast. Biochem Pharmacol 1992; 44, 617-620.
7. 324Pro) expressed by recombinant baculovirus in insect cells. Naunyn-Schmiedeberg's Arch Pharmacol 1997; 355, 309-318.
8. Forrester LM, Henderson CJ, Glancey MJ, Back DJ, Park BK, Ball SE, Kitteringham NR, McLaren AW, Miles JS, Skett P, Wolf CR. Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J 1992; 281, 359-368.
9. Gillam EMJ, Baba T, Kim B-R, Ohmori S, Guengerich PP. Expression of modified human cytochrome P450 5A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch Biochem Biophys 1993; 305, 123-131.
10. Gillam EMJ, Guo Z, Martin MV, Jenkins CM, Guengerich FP. Expression of cytochrome P450 2D6 in Escherichia coli, purification, and spectral and catalytic characterization. Arch Biochem Biophys 1995; 319, 540-550.
11. John GH, Hasler JA, He Y, Halpert JR. Escherichia coli expression and characterization of cytochromes P450 2B11, 2B1 and 2B5. Arch Biochem Biophys 1994; 314, 367-375.
12. 2+-chelate affinity purification, and characterization of solubility and aggregation. Arch Biochem Biophys 1995; 321, 277-288.
13. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus, sequence and identification of the polymorphic CYP2D6 gene, a related gene and a pseudogene. Am J Hum Genet 1989; 45, 889-904.
14. Kroemer HK, Eichelbaum M. 'It's the genes, stupid'. Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 1995; 56, 2285-2298.
15. Kronbach T, Mathys D, Gut J, Catin T, Meyer UA. High-performance liquid Chromatographie assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal Biochem 1987; 162, 24-32.
16. Krynetski EY, Drutsa VL, Kovaleva IE, Luzikov VN. High yield expression of functionally active human liver CYP2D6 in yeast cells. Pharmacogenetics 1995; 5, 103-109.
17. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227, 680-685.
18. Macart M, Gerbaut L. An improvement of the Coomassie Blue dye binding method allowing an equal sensitivity to various proteins: application to cerebrospinal fluid. Clin Chim Acta 1982; 122, 93-101.
19. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2, 584-586.
20. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. J. Biol Chem 1964; 239, 2370-2378.
21. Otton SV, Crewe HK, Lennard MS, Tucker GT, Woods HF. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther 1988; 247, 242-247.
22. Paine MJI, Gilham D, Roberts GCK, Wolf CR. Functional high level expression of cytochrome P450 CYP2D6 using baculoviral expression systems. Arch Biochem Biophys 1996; 328, 143-150.
23. Penman BW, Recce J, Smith T, Yang CS, Gelboin HV, Gonzalez FJ, Crespi CL. Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6. Pharmacogenetics 1993; 3, 28-39.
24. Pritchard MP, Ossetian R, Li DN, Henderson CJ, Burchell B, Wolf CR, Friedberg T. A general strategy for the expression of recombinant human cytochrome P450s in Escherichia coli using bacterial signal peptides: expression of CYP3A4, CYP2A6 and CYP2E1. Arch Biochem Biophy 1997; 345, 342-354.
25. Richardson TH, Jung F, Griffin KJ, Wester M, Raucy JL, Kemper B, Bornheim LM, Hassett C, Omiecinski CJ, Johnson EF. A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli. Arch Biochem Biophys, 1995; 323, 87-96.
26. Rose RE. The nucleotide sequence of pACYC184. Nucl Acids Res 1988; 16, 355.
27. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 50 Japanese and 50 Caucasians. J Pharmacol Exp Ther 1994; 270, 414-423.
28. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76, 4350-4354.
29. Vermilion JL, Coon MJ. Purified liver microsomal NADPH-cytochrome P-450 reductase. Spectral characterization of oxidation-reduction states. J Biol Chem 1978; 253, 2694-2704.
30. Waterman MR, Jenkins CM, Pikuleva I. Genetically engineered bacterial cells and applications. Toxicol Lett 1995; 82/83, 807-813.
31. Waxman DJ, Lapenson DP, Aoyama T, Gelboin HV, Gonzalez FJ, Korzekwa K. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys 1991; 290, 160-166.
32. Yamazaki H, Ueng, Y-F, Shimada T, Guengerich FP. Roles of divalent metal ions in oxidations catalyzed by recombinant cytochrome P450 3A4 and replacement of NADPH-cytochrome P450 reductase with other flavoproteins, ferredoxin, and oxygen surrogates. Biochemistry 1995; 34, 8380-8389.
33. Yon J, Fried M. Precise gene fusion by PCR. Nucl Acids Res 1989; 17, 4895.